At scPharmaceuticals, we believe the most significant advances in outpatient care will be achieved by applying state-of-the-art science and technologies to optimize treatment options for patients. Our goal is to provide targeted solutions for patient populations and disease states where outpatient management will have the greatest systemic impact.
Through a multi-year effort—and by continually challenging our own assumptions—we have developed what we believe is an ideal drug delivery system for our lead program. FUROSCIX® is an investigational, proprietary, pH neutral formulation of furosemide that is designed for administration by subcutaneous infusion via an on-body, wearable, patient centric, drug delivery system currently undergoing research. FUROSCIX is under development as a potential outpatient IV-strength diuretic for the treatment of congestion and edema in patients with heart failure who display a reduced responsiveness to oral diuretics and who do not require hospitalization. Investigational FUROSCIX pairs our proprietary subcutaneous formulation of furosemide with West Pharmaceutical Services, Inc.’s SmartDose® Generation II (Gen. II) on-body drug delivery system designed for optimal administration and ease of use.
if approved, the wearable SmartDose drug delivery system will allow patients to self-administer FUROSCIX in accordance with their prescribed treatment
The SmartDose Gen. II device is under development to be a fully integrated, single-use subcutaneous drug delivery system designed with a variety of easy-to-use features—including pre-filled cartridges; a pre-programmed drug delivery profile; and visual, tactile, and audible feedback to ensure correct operation and boost user confidence. SmartDose drug delivery system could offer a targeted solution.
the underlying SmartDose technology has been previously FDA- and EMA-approved as part of a combination product
The original SmartDose Gen. I device—designed for delivery volumes of 3.5 mL—was a component of a previously approved combination therapy for delivery of a different drug product that received approval from the U.S. Food and Drug Administration. Based on the previous positive regulatory evaluations of the SmartDose Gen. I device, we elected to evaluate investigational FUROSCIX with the Gen. II SmartDose device (shown below), which has increased delivery volume of 10 mL and the potential to provide IV-strength diuresis with the advantages of at-home care.
Patient-centric features include:
pre-filled, single-use cartridges for easy user-loading
a pre-programmed drug delivery profile
visual, tactile, and audible feedback to boost user confidence
a fully integrated delivery system